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Abstract: Complexes of the type [ML′L(OH)(H2O)], where M = Ni(II), Co(II) 
or Mn(II), L′ = isatin and HL = 3-(2-phenylhydrazono)acetylacetone, 3-(2-(4- 
-chlorophenyl)hydrazono)acetylacetone or 3-(2-(4-bromophenyl)hydrazono)-
acetylacetone, were synthesized by equimolar reaction of a metal(II) chloride 
with isatin and a 3-(2-arylhydrazono)acetylacetone. The resulting complexes 
were characterized by elemental analyses, molar conductivity, spectral data (IR 
and mass spectrometry) and magnetic moments. Furthermore, the ligands and 
their metal complexes were screened for their cytotoxicity against different 
human cancer cell lines using the sulforhodamine B (SRB) assay. The results 
showed that most of the mixed ligand metal complexes have high cytotoxicity 
in comparison with the reference drugs used. 
Keywords: 3-(2-arylhydrazono)acetylacetone; isatin; transition metals; mixed 
ligands; cytotoxicity. 
INTRODUCTION 
One of the main goals for research chemists and pharmacologists is the syn-
thesis of novel bioactive compounds for the development of better drugs to fight 
diseases. Thus, coordination chemistry has developed very rapidly mainly in the 
last 15 years since many ligands of no or low biological activity become more 
active when transferred to their metal complexes1,2 and some drugs show 
increased activity when administered as metal complexes.3–5 In addition, com-
plexes containing heterocyclic ligands having nitrogen and/or sulfur have inc-
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reased biological activities compared to the original ligands.6,7 Recently, there is 
an increasing interest in the synthesis of mixed ligand metal complexes due to 
their biological significance. These complexes play important roles in biological 
processes since enzymes are known to be activated by metal ions.8,9 Moreover, 
they have wide antituberculosis, antifungal,10 antibacterial11 and antitumor12,13 
pharmacological activities. 
A literature survey reveals that isatin (indole-2,3-dione) and its derivatives 
shows a wide range of antimicrobial,14 anticonvulsant,15 anticancer16,17 and anti-
HIV activities.18 On the other hand, arylhydrazono-1,3-diketone derivatives have 
been widely used as intermediates in the preparation of a large number of 
biologically important heterocyclic compounds.19–21 
In view of these facts and continuing our interest in the synthesis of com-
pounds with promising biological activities,
22,23 Ni(II), Co(II) and Mn(II) com-
plexes of 3-(2-arylhydrazono)acetylacetone with isatin were prepared and charac-
terized by IR and UV–Vis spectroscopy, elemental analyses, molar conductivity 
and magnetic susceptibility measurements. The study was extended to screen the 
ligands and their metal complexes against different human cancer cell lines. 
EXPERIMENTAL 
Chemistry 
All melting points were measured on a Gallenkamp melting point apparatus and are 
uncorrected. The IR spectra were recorded (KBr disk) on a Perkin-Elmer 1650 FT-IR ins-
trument. The 1H-NMR (500 MHz) spectra were recorded on a Varian 500 MHz spectrometer 
in DMSO-d6 using TMS as an internal standard. The FAB mass spectra of the complexes 
were recorded on a JEOL JMS/AX-500 mass spectrometer. Elemental analyses were obtained 
from the Micro Analytical Data Center at Cairo University, Egypt. The magnetic suscept-
ibilities were measured at 20 °C by the Gouy method at the Faculty of Science, Cairo Uni-
versity. The electronic absorption spectra were recorded on a PG Instruments Ltd., +80+ 
automatic UV–Vis spectrophotometer in DMSO. The molar conductance values of solutions 
of the metal complexes in DMF (10-3 mol L-1) were measured using Metrohem 660 con-
ductivity meter. 
Acetylacetone, p-chloroaniline, p-bromoaniline, aniline, sodium acetate, methanol and 
hydrochloric acid were of Merck AR grade, Germany. Isatin was supplied by Riedel de Haën 
AG, Germany. The employed NiCl2·6H2O, CoCl2·6H2O and MnCl2·4H2O salts (Fluka, Ger-
many) were of AR grade. 
Preparation of 3-(arylhydrazono)acetylacetones) 
The 3-(arylhydrazono)acetylacetone derivatives (HL) were prepared by coupling acetyl-
acetone with different diazonium salts. Thus, a solution of acetylactone (0.01 mol) and sodium 
acetate (5 g) in ethanol (50 mL) was cooled to 0–5 °C and then the diazonium salt (0.01 mol) 
was added under stirring. The reaction was allowed to proceed at 0–5 °C for 30 min. The 
3-(arylhydrazono)acetylacetone derivatives were precipitated and collected by filtration, 
washed with cold deionized water and recrystallized from ethanol.24 
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Preparation of the complexes 1–9 
A solution of the metal chloride (3.4 mmol) in a minimum amount of water was added to 
a hot solution of the mixed ligand (3.4 mmol) in methanol, whereby a clear solution was 
obtained. The pH was increased from 6.0 to 8.0 with dilute NaOH solution. The mixture was 
refluxed under stirring for 6 h. The formed complex was filtered off, washed several times 
with hot methanol and dried under reduced pressure. 
Biological experiments 
In vitro cytotoxicity screening. The tested compounds were subjected to in vitro disease- 
-oriented primary antitumor screening. Different tumor cell lines were utilized. The human 
tumor cell lines of the cancer screening panel were grown in RPMI 1640 medium containing 5 % 
fetal bovine serum and 2 mM L-glutamine. In a typical screening experiment, 100 µL of cells 
were inoculated into 96-well microtiter plates at plating densities ranging from 5000 to 40000 
cells well-1, depending on the doubling time of the individual cell lines. After cell inoculation, 
the microtiter plates were incubated at 37 °C, 5 % CO2, 95 % air and 100 % relative humidity 
for 24 h prior to the addition of the experimental drugs. After 24 h, two plates of each cell line 
were also fixed in situ with trichloroacetic acid (TCA) to represent a measurement of the cell 
population for each cell line at the time of drug addition (Tz). Experimental drugs were 
solubilized in DMSO at 400-fold of the desired final maximum test concentration and stored 
frozen prior to use. At the time of drug addition, an aliquot of frozen concentrate was thawed 
and diluted to 2-times the desired final maximum test concentration with complete medium 
containing 50 µg ml-1 gentamicin. Four additional 10-fold or 0.5log serial dilutions were made 
to provide a total of five drug concentrations plus a control. Aliquots of 100 µL of these 
different drug dilutions were added to the appropriate microtiter wells already containing 100 
µL of medium, resulting in the required final drug concentrations. Following drug addition, 
the plates were incubated for an additional 48 h at 37 °C, 5 % CO2, 95 % air and 100 % 
relative humidity. For adherent cells, the assay was terminated by the addition of cold TCA. 
The cells were fixed in situ by the gentle addition of 50 µL of cold 50 % (w/V) TCA (final 
concentration, 10 % TCA) and incubated for 60 min at 4 °C. The supernatant layer was 
discarded and the plates were washed five times with tap water and air-dried. Sulforhodamine 
B (SRB) solution (100 µL) at 0.4 % (w/V) in 1 % acetic acid was added to each well and the 
plates were incubated for 10 min at room temperature. After staining, the unbound dye was 
removed by washing five times with 1 % acetic acid and the plates were air dried. The bound 
stain was subsequently solubilized with 10 mM Trizma® base and the absorbance was read on 
an automated plate reader at a wavelength of 515 nm. For suspension cells, the methodology 
was the same except that the assay was terminated by fixing the settled cells at the bottom of 
the wells by gently adding 50 µL of 80 % TCA (final concentration, 16 % TCA). The 
parameter IC50 which is the concentration of the drugs inducing a 50% inhibition of cell 
growth of treated cells when compared to the growth of control cells.25-27 
RESULTS AND DISCUSSION 
Chemistry 
The ligands. The 3-(arylhydrazono)acetylacetone derivatives (HL) are pre-
pared via coupling between diazotized aromatic amine derivatives and acetyl-
acetone in a 1:1 molar ratio according to Scheme 1.24 The structures of these 
ligands were confirmed by elemental analyses and their spectral data (IR and 
1H-NMR), which are discussed later with their metal complexes. 
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Scheme 1. Synthesis of 3-(arylhydrazono)acetylacetone derivatives (HL). 
The complexes. Reactions of the hydrated metal(II) chloride with 3-(arylhyd-
razono)acetylacetone and isatin in equimolar ratios resulted in formation of the 
complexes 1–9, shown in Scheme 2. 
The physical, analytic and spectral data for the ligand and their metal 
complexes are given in the Supplementary material to this paper. 
Infrared spectra of the ligands and their complexes 
In the infrared spectra of the ligands (HL1, HL2 and HL3), the broad band in 
the range 3428–3086 cm–1 indicates the existence of strong intramolecular hyd-
rogen bonding.28 Furthermore, there are two strong bands at 1673 and 1623 cm–1 
assignable to ν(C=O, free) and ν(C=O, hydrogen bonded), respectively. The 
ν(C=N) band appears at 1593 cm–1, which remains almost unaffected in the 
spectra of all the complexes suggesting that the nitrogen atom is not involved in 
the coordination, while the ν(C=O) band at 1623 cm–1 is shifted to lower fre-
quencies in the spectra of the complexes, suggesting that this oxygen atom is 
involved in the coordination, while the carbonyl group at ≈1673 cm–1 remains 
almost unchanged in the spectra. The prominent band present at ≈1518 cm–1 of 
the ligands is due to δ(N–H) vibrations, which disappears in the spectra of all the 
complexes because of the replacement of the hydrazone NH proton with a metal 
ion. The infrared spectrum of isatin (L′) shows a band at 3191 due to ν(N–H) and 
two ν(C=O) group absorptions at 1745 and 1731 cm–1. The IR spectra of the 
complexes show that the two carbonyl groups of isatin ligand are shifted to lower 
frequency, suggesting that both groups are involved in the coordination, while 
ν(N–H) at 3191 cm–1 is not changed, indicating that the (N–H) group is not 
involved in the coordination. 
Conclusive evidence of bonding was also given by the observation that new 
bands in the spectra of all metal complexes 1–9 appear in the low frequency 
regions at 493–438 and 584–540 cm–1 characteristic of ν(M–O) and ν(M–N) 
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stretching vibrations, respectively.29 Furthermore, the observed broad band at 
3550 cm–1 in all complexes were attributed to the OH group and the OH stretch-
ing vibrations of lattice water molecules.10 
 
Scheme 2. Synthesis of mixed ligand complexes of the type [ML′L(OH)(H2O)]. 
Nuclear magnetic resonance of the ligands 
The 1H-NMR spectrum of HL revealed a single proton at δ ≈14.02 ppm due 
to the N–H…O=C group.30,31 The 1H-NMR spectrum of HL2 is illustrated in 
Fig. S-1 of the Supplementary material to this paper.  
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Mass spectra of the complexes 
The molecular ion peaks in the mass spectra of some complexes were used 
to confirm the molecular formula. Thus, the mass spectra of the Ni(II) complexes 
confirmed the molecular formulas, e.g., [NiL′L1(OH)(H2O)] and 
[NiL′L3(OH)(H2O)] confirmed C19H19N3NiO6 and C19H18BrN3NiO6, respect-
ively. Similarly, the mass spectra of the Co(II) complexes confirmed the mole-
cular formulas, e.g., [CoL′L2(OH)(H2O)] and [CoL′L3(OH)(H2O)] confirmed the 
molecular formulas C19H18ClCoN3O6 and C19H18BrCoN3O6, respectively. 
Moreover, the mass spectrum of the Mn(II) complex, e.g., [MnL′L3(OH)(H2O)] 
confirmed the molecular formula C19H18BrMnN3O6. 
Electronic spectra and magnetic moments 
The UV–visible spectra of the free ligands HL1, HL2, HL3 and L′ showed 
absorption bands at 292–297 and 418–440 nm due to π→π* and n→π* trans-
itions, respectively. These bands were blue- or red-shifted in the spectra of the 
complexes due to coordination in the ligands. 
The Mn(II) complexes 3, 6 and 9 exhibited two weak bands at 618–622 and 
520–526 nm which were attributed to 6A1g → 4T1g(4G) and 6A1g → 4T2g(4G) 
transitions, respectively. These absorptions are consistent with an octahedral geo-
metry around the Mn(II) atom. The magnetic moment values of the Mn(II) com-
plexes were in the range of 5.82–5.90 μB, corresponding to five unpaired elec-
trons, which is also indicative of octahedral geometry.33 
The electronic spectra of the Co(II) complexes 5 and 8 showed two d–d 
transitions in the ranges 654–661 and 540–548 nm due to the 4T1g(F) → 4A2g(F) 
and 4T1g(F) →  4A2g(p) transitions, respectively, indicating an octahedral con-
figuration around the Co(II) atom. The 4T2g(F) → 4T1g(F) transition (1237–1242 
nm) would be observed in the near IR region. This region was out the range of 
the employed spectrophotometer.34 The µeff values for the Co(II) complexes 
were in the range 4.87–4.94 μB, which are similar to those reported for octa-
hedral Co(II).35 
The Ni(II) complexes 1,  4 and 7 exhibited two absorption bands in the 
ranges 963–988 and 572–581 nm, which are assigned to 3A2g(F) → 3T2g(F) and 
3A2g(F) → 3T1g(F) transitions, respectively. However, the absorption bands at 
420–422 nm due to 3A2g(F) → 3T1g(p) was overlapped with the ligand absorp-
tion bands. The spectra of these complexes support an octahedral stereochemistry 
around the Ni(II) atom. The room temperature magnetic moment values of the 
Ni(II) complexes were 3.17–3.20 μB, which are in the normal range observed for 
octahedral Ni(II) complexes.36 
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Molar conductance measurements 
The molar conductivities of 10–3 mol L–1 solutions of the complexes in 
DMF were measured at room temperature. The results were in the range 22.1– 
–11.6 Ω–1 cm2 mol–1, indicating that all the metal complexes had molar con-
ductance values in the range characteristic for non-electrolytes.37 
Biological activity 
In vitro cytotoxicity screening. The cytotoxicities of the mixed ligand com-
plexes [ML′L(OH)(H2O)], the ligands HL1–HL3 and L′ were determined using 
the SRB assay on different human cancer cell lines including: cervical carcinoma 
(KB), ovarial carcinoma (SK OV-3), CNS cancer (SF-268), non-small cell lung 
cancer (NCl H460), colon adenocarcinoma (RKOP 27) (Table I), anti-leukemia 
(HL60, U937, K562), melanoma (G361, SK-MEL-28) and neuroblastoma 
(GOTO, NB-1) (Table II). The cytotoxic effect of the ligands and their metal 
complexes [ML′L(OH)(H2O)] on the cell lines HeLa (cervical), MCF-7 (breast), 
HT1080 (fibrosarcoma) and HepG2 (liver) were also tested (Table III). The 
results are expressed as the IC50, which is the concentration of a drug that causes 
a 50 % reduction in the proliferation of cancer cells when compared to the 
growth of the control cells. 
TABLE I. Cytotoxicity (IC50 / nM, the concentration required for 50 % inhibition of cell 
growth) of the ligands and the mixed ligand complexes determined by using SRB assay on 
different human cancer cell lines; the values for most potent compound are marked by “*” 
The ligands and their 
metal complexes 
Cell line 
KB  SK OV-3  SF-268  NCI H460  RKOP27 
L′ 4.40  5.40  4.50  0.65  7.50 
HL1 6.70  5.46  0.35*  0.89  2.30* 
1   0.32* 3.20 0.55  0.44  4.30 
2  4.40 3.40  3.50  0.40*  5.50 
3  5.60 6.70  0.43 0.56  7.60 
HL2 9.80  8.80  9.90  0.68  4.50 
4  0.55 0.55*  5.60  0.66  7.80 
5  0.45 8.80  0.50 0.43  8.80 
6  0.45 7.60  0.40 0.67  6.40 
HL3 0.65  0.67  4.50  0.87  4.80 
7  8.00 7.70  0.75 0.57  4.30 
8  0.67 5.60  0.65 0.43  4.50 
9  0.90 0.89  0.85 0.84  2.30* 
Fluorouracil 4.46  –  –  –  – 
Doxorubicin –  4.16  –  –  – 
Cytarabine –  –  7.68  –  – 
Gemcitabine HCl  –  –  –  2.13  – 
Capecitabine –  –  –  –  4.33 
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TABLE II. Cytotoxicity (IC50 / nM, the concentration required for 50 % inhibition of cell 
growth) of the ligands and the mixed ligand complexes determined by using SRB assay on 
different human cancer cell lines; the values for most potent compound are marked by “*” 
The ligands and their 
metal complexes 
Cell line 
Leukemia Melanoma  Neuroblastoma 
HL60 U937  K562  G361 SK-MEL-28 GOTO  NB-1 
L′ 8.00  6.80  3.70  0.43* 5.00  0.65  4.80 
HL1 6.50  7.70  0.87  0.87  4.00  3.00  3.60 
1  0.75 9.00  0.60  0.57  4.00  6.80  9.87 
2  5.30 5.40  5.40  0.77  5.00  5.87  3.00 
3  3.40 7.30  0.60  0.88 1.00*  7.60  4.00 
HL2 6.00  8.70  9.00  0.50  8.00  7.50  2.30 
4  0.44 0.65  6.00  8.80  4.00  0.57  0.70 
5  0.56 3.50  0.68  0.64  6.00  0.68  0.69 
6  0.32* 6.00 0.90  0.59  8.00  0.67  0.56 
HL3 0.67  0.43*  6.40  0.54  7.00  4.70  0.36* 
7  8.00 6.30  0.40*  0.70  8.00  0.50  7.60 
8  0.33 8.00  0.50  0.70  7.00  0.34*  9.00 
9  0.80 0.79  8.00  0.60  8.00  0.56  0.65 
Doxorubicin 1.13  4.45  6.66  –  –  4.73  5.15 
Aldesleukin –  –  –  6.66  3.45  –  – 
TABLE III. Cytotoxicity (IC50 / nM, the concentration required for 50 % inhibition of cell 
growth) of the ligands and the mixed ligand complexes determined by using SRB assay on 
different human cancer cell lines; the values for most potent compound are marked by “*” 
The ligands and their 
metal complexes 
Cell line 
HeLa 
(cervical) 
MCF-7 
(breast) 
HT1080 
(fibrosarcoma) 
HepG2 
(liver) 
L′ 0.449  3.650  7.86  2.30 
HL1 9.860  0.790  0.45  0.64 
1  0.009* 9.600  0.09*  0.80 
2  7.680 8.400  8.69  0.79 
3  0.897 4.587  0.54  0.47 
HL2 6.600  7.600  5.80  3.64 
4  0.780 0.900  3.65  0.77 
5  5.640 4.970  0.99  0.91 
6  0.600 0.764  0.87  0.89 
HL3 0.960  5.800  2.50  0.54* 
7  6.500 9.600  0.86  8.50 
8  0.770 4.600  7.00  0.79 
9  0.444 0.760*  0.59  6.50 
Tamoxifen 0.114  0.155  1.16  1.31 
Screening the cytotoxicity of the mixed ligand complexes [ML′L(OH)(H2O)] 
and the ligands HL1, HL2, HL3 and L′ on cervical carcinoma (KB), where 5-fluo-
rouracil was used as a standard drug (IC50 = 4.46 nM), shows that the complexes 
1, 4, 5, 6, 8, and 9, and the ligand HL3 were more potent than the standard drug. 
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In the case of the ovarial carcinoma (SK OV-3) cell line, the tested com-
plexes 4 and 9 and the ligand HL3 (IC50 = 0.55, 0.89 and 0.67 nM, respectively) 
were found to be more potent than the standard drug doxorubicin (IC50 = 4.16 nM). 
Studying the cytotoxicity of the tested complexes and the ligands on the 
CNS cancer (SF-268) cell line using cytarabine (IC50 = 7.68 nM) as a standard 
drug, reveals that all the tested complexes and the ligands except HL2 (IC50 = 
= 9.90 nM) were more potent than the standard drug. 
In the case of the non-small cell lung cancer (NCl H460) cell line, all of the 
tested complexes and the ligands were found to be more potent than the standard 
drug gencitabine hydrochloride (IC50 = 2.13 nM). 
In the case of the colon adenocarcinoma (RKOP 27) cell line, the ligand HL1 
and the complex 9 (IC50 = 2.30 nM) were found to be more potent than the 
standard drug capecitabine (IC50 = 4.33 nM). 
The study of the cytotoxicity on the leukemia (HL60) cell line indicated that 
the ligands L′, HL1, HL2 and the complexes 2, 3 and 7 were less potent com-
pounds than doxorubicin (IC50 = 1.13 nM). 
In the case of the leukemia (U937) cell line, the ligand HL3 (IC50 = 0.43 
nM) was the most potent, while complex 1 (IC50 = 9.00 nM) was the least bio-
active. 
In the case of the leukemia (K562) cell line, the tested complexes and the 
ligands, except ligand HL2 and complex 9, were more active than the standard 
drug doxorubicin (IC50 = 6.66 nM); the ligand HL3 and complex 4 had activity 
comparable to that of doxorubicin. 
On estimation of the cytotoxicity on the melanoma (G361) cell line, the 
tested complexes and the ligands, expect complex 4 (IC50 = 8.80 nM) were more 
active than the standard drug aldesleukin (IC50 = 6.66 nM).  
In the case of the melanoma (SK-MEL-28) cell line, the tested complexes 
and the ligands were less active than the standard drug Aldesleukin (IC50 = 3.45 
nM), expect complex 3 that was more active (IC50 = 1.00 nM) 
Cytotoxicity of the tested complexes and the ligands on neuroblastoma 
(GOTO) cell line showed that complex 8 was the most potent (IC50 = 0.34 nM) 
and more active than the standard drug doxorubicin (IC50 = 4.73 nM). 
In the case of the neuroblastoma (NB-1) cell line, complex 2 was less active 
than the standard drug doxorubicin (IC50 = 5.15 nM), while ligand HL3 (IC50 =  
= 0.36 nM) was the most active. 
The cytotoxicity of the tested complexes and the ligands on the HeLa (cer-
vical) cell line showed that complex 1 (IC50 = 0.009 nM) was the most potent 
and more active than the standard drug tamoxifen (IC50 = 0.114 nM). 
In the case of the MCF-7 (breast) cell line, the standard drug tamoxifen (IC50 =  
= 0.155 nM) was more active than all the other tested complexes and ligands. 
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In the case of the HT1080 (fibrosarcoma) cell line, complex 1 (IC50 = 0.09 
nM) was the most potent and complex 2 (IC50 = 8.69 nM) was found to be less 
potent than tamoxifen (IC50 = 1.16 nM). 
The cytotoxicity of the tested complexes and the ligands on the HepG2 
(liver) cell line shows that the complexes 1–6 and 8, and the ligands HL3 and 
HL1  were more active than the standard drug tamoxifen (IC50 = 1.16 nM), 
whereby complex 3 (IC50 = 0.47 nM) was the most promising one. 
CONCLUSIONS 
Ni(II), Co(II) and Mn(II) complexes of 3-(2-arylhydrazono)acetylacetone 
(HL) and isatin (L′) were synthesized. The ligands (L′ and HL1–HL3) act as 
bidentate molecules, whereby L′ was coordinated through two oxygen atoms 
while the 3-(2-arylhydrazono)acetylacetones were coordinated by oxygen and 
nitrogen atoms. The prepared complexes 1–9, which were non-electrolytes, have 
octahedral geometry with the general structural formula [ML′L(OH)(H2O)]. The 
cytotoxicity results of the ligands and their complexes 1–9 against different 
human cancer cell lines indicated that most of the complexes exhibited high cyto-
toxicity at very low concentrations in comparison with the reference drugs con-
sidered. 
SUPPLEMENTARY MATERIAL 
Physical, analytic and spectral data of the ligands and complexes are available elec-
tronically at http://www.shd.org.rs/JSCS/, or from the corresponding author on request. 
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У  реакцијама  одговарајућег  метал(II)-хлорида  са  изатином  и 3-(2-арилхидразо-
но)ацетилацетоном синтетизовани су комплекси опште формуле [ML′L(OH)(H2O)] (где 
је М = Ni(II), Co(II) или Mn(II), L′ = изатин и HL = 3-(2-фенилхидразоно)ацетилацетон, 
3-(2-(4-хлорфенил)хидразоно)aцетилацетон  или 3-(2-(4-бромфенил)хидразоно)aце-
тилацетон). Комплекси су окарактерисани применом елементалне микроанализе, спек-
троскопских метода (IR спектроскопија и масена спектрометрија) и мерењем моларне 
проводљивости и магнетног момента. Испитивана је цитотоксична активност лиганда и 
комплекса  на  различитим  туморским  ћелијским  линијама  применом SRB теста. 
Добијени  резултати  су  показали  да  већина  комплекса  показује  већу  цитотоксичну 
активност у поређењу са стандардним лековима.  
(Примљено 13. августа, ревидирано 31. октобра, прихваћено 15. новембра 2013) 
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